Study Details

Back to Search Results

Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03941483

Astellas Study ID

The unique identification code given by the study sponsor.

1128-CL-0201

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Kidney Disease

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

35 years - N/A

Sex

Female & Male

Product

ASP1128

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Nov 2019 - Oct 2021

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

351

A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Keck School of Medicine USC

Los Angeles, United States, 90033

ProMedica Toledo Hospital

Toledo, United States, 43606

Sarver Heart Center

Tucson, United States, 85724

Baylor Scott & White Heart Hospital

Plano, United States, 75093

Florida Hospital Pepin Heart Institute

Tampa, United States, 33613

Indiana University Health Ball Memorial Hospital

Muncie, United States, 47303

Delmarva Heart, LLC

Salisbury, United States, 21804

WVU Heart and Vascular Institute

Morgantown, United States, 26506

St. Vincent Heart Center

Indianapolis, United States, 46290

Minneapolis Heart Institute

Minneapolis, United States, 55407

Ascension Genesys Hospital

Grand Blanc, United States, 48439

JEHM clinical Research Group

Palm Springs, United States, 92262

Fairview Hospital - Cleveland Clinic

Cleveland, United States, 44111

Maine Medical Center

Portland, United States, 04102

Inova Heart and Vascular Institute

Falls Church, United States, 22042

University of Texas Health Science Center

San Antonio, United States, 78229

VA Medical Center

Washington, United States, 20422

Health Park Medical Center

Fort Myers, United States, 33908

University of Florida- Jacksonville

Jacksonville, United States, 32209

Baptist Medical Center

Jackson, United States, 39202

Medical City Dallas Hospital

Dallas, United States, 75230

Southern Illinois University

Springfield, United States, 62794

Vanderbilt University

Nashville, United States, 37232

Shands Hospital

Gainesville, United States, 32610

IU Health - Methodist

Indianapolis, United States, 46202

Duke University Medical Center

Durham, United States, 27710

Luthern Medical Group

Fort Wayne, United States, 46804

Barnes Jewish Hospital

St. Louis, United States, 63110

Lourdes Cardiology Services

Voorhees, United States, 08035

Hartford Hospital

Hartford, United States, 06102

Jacksonville Center for Clinical Research

Jacksonville, United States, 32207

Heart Center Research, LLC

Huntsville, United States, 35801

Morton Plant Hospital

Clearwater, United States, 33756

Moses H. Cone Memorial Hospital

Greensboro, United States, 27401

Mid Michigan Medical Center

Midland, United States, 48670

University Hospitals - Cleveland Medical Center

Cleveland, United States, 44106

MercyOne Iowa Heart Center

Des Moines, United States, 50314

University of Utah Hospitals and Clinics

Salt Lake City, United States, 84132

University of Oklahoma

Oklahoma City, United States, 73104

University of Virginia Health System

Charlottesville, United States, 22908

St. Luke's Hospital of Kansas City

Kansas City, United States, 64111

Columbia University Irving Medical Center

New York, United States, 10032

Medical University of South Carolina

Charleston, United States, 29425

Temple University Hospital

Philadelphia, United States, 19140

Suburban Hospital Inc

Bethesda, United States, 20814

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo